Biocon Limited’s shares surged nearly 3% to ₹366.75 on January 31 following the announcement of its Q3 FY25 financial results. The company reported all-round growth across its business segments, with revenue and profitability showing a steady rise despite the absence of last year’s exceptional gains. Biocon’s operating revenue for Q3 FY25 stood at ₹3,821 crore, reflecting a 10% year-on-year growth. The total revenue for the quarter came in at ₹3,856 crore, marking a 7% increase from the corresponding period last year.
EBITDA for the quarter rose 16% YoY to ₹787 crore, supported by robust operational performance across its biologics, generics, and research services segments. However, net profit figures presented a different picture, as the base quarter of Q3 FY24 included significant one-time gains of ₹350 crore from the partial divestment of the Branded Formulations India (BFI) business and ₹456 crore from Biocon’s stake dilution in Bicara Therapeutics.
Excluding these exceptional items, Biocon’s adjusted operational growth demonstrates resilience despite challenges. The stock’s upward movement highlights investor confidence in its core business expansion and future growth prospects.
As of the latest market session, Biocon’s market capitalization stands at ₹415.8 billion, with a year range between ₹244.55 and ₹404.70.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Always conduct your research or consult a financial advisor before making investment decisions
